Nordic Pharma to Showcase LACRIFILL at AAO 2025
Nordic Pharma, a proud subsidiary of Nordic Group B.V., is set to showcase its revolutionary LACRIFILL Canalicular Gel, a novel treatment aimed at alleviating symptoms of dry eye. This anticipated event will take place at the American Academy of Ophthalmology (AAO) Annual Meeting, where healthcare professionals eager to enhance their knowledge about ophthalmic advancements are expected to attend.
A Promising Response from Patients
At the upcoming meeting, Nordic Pharma will provide insights into impressive patient feedback regarding their LACRIFILL Canalicular Gel. Reports highlight that an overwhelming 98.11% of both new and returning patients said they would opt for additional doses after trying the treatment. This revelation, as shared by the Chief Commercial Officer of Eye Care U.S., Jai Parekh, showcases the therapy's positive reception and its importance in the ophthalmology field.
Collaborative Research and Innovations in Ophthalmology
In addition to unveiling patient data, esteemed professionals including Vance Thompson, MD, Kayla Karpuk, OD, and Mark Packer, MD, are collaboratively authoring an article titled "Critical Perspectives" in the respected journal Expert Review of Ophthalmology. This piece emphasizes the critical role that managing dry eye can play in ensuring successful surgical outcomes for cataract and refractive procedures. Lead author Vance Thompson highlights that LACRIFILL can be advantageous for preoperative planning by optimizing the ocular surface before surgery and continuing to provide benefits during recovery.
Supporting Women in Ophthalmology
Moreover, on the evening of October 18, Nordic Pharma will honor its commitment to supporting women in the field with its role as Premier Sponsor of the Women in Ophthalmology (WIO) Awards Ceremony. This esteemed event acknowledges and celebrates the accomplishments of women professionals in ophthalmology, and Nordic Pharma's support further emphasizes its dedication to advancing equal representation within the industry.
Experience LACRIFILL Firsthand at AAO
Conference attendees are encouraged to visit booth #1401 for special injection demonstration sessions, providing a hands-on approach to experiencing LACRIFILL Canalicular Gel. The opportunity to connect directly with representatives and place orders at this booth illustrates Nordic Pharma's commitment to improving healthcare solutions.
New Insights from TFOS DEWS III Report
Recent findings from TFOS DEWS III, published in the esteemed American Journal of Ophthalmology, highlight two significant studies on Nordic Pharma's LACRIFILL. The findings suggest remarkable improvements in dry eye symptoms, including corneal staining and other critical indicators following three months of treatment. In a comparison with a standard hydrogel canalicular plug, LACRIFILL was noted for its safety and efficacy, delivering sustainable improvements in patient-reported outcomes over a six-month period.
About Nordic Group B.V.
Nordic Group B.V. represents a privately held, medium-sized international pharmaceutical organization dedicated to the innovation and commercialization of specialized medical products. Their strategic focus has led to portfolio enhancement through carefully targeted developments and acquisitions, particularly in areas such as Eye Care, Rheumatology, and Women’s Health. With established roots in Europe, Nordic Group is actively expanding its global footprint through selective acquisitions.
About Nordic Pharma, Inc.
Being a vital subsidiary of Nordic Group B.V., Nordic Pharma, Inc. collaborates with well-regarded global biopharmaceutical firms. This positioning enables Nordic Pharma to adeptly leverage its capabilities in bringing biotechnology-derived medicines, along with expert sterile manufacturing processes and proprietary delivery technologies, to market.
Frequently Asked Questions
What does LACRIFILL Canalicular Gel do?
LACRIFILL Canalicular Gel is a novel therapy designed to alleviate symptoms associated with dry eye.
When will the AAO meeting take place?
The American Academy of Ophthalmology Annual Meeting is scheduled for October 18-20.
How do patients respond to LACRIFILL?
Recent surveys indicate that 98.11% of patients expressed a willingness to return for follow-up treatment with LACRIFILL.
What role does Nordic Pharma play at AAO?
Nordic Pharma will act as a Premier Sponsor for the Women in Ophthalmology Awards and will showcase LACRIFILL at their booth.
What does Nordic Group B.V. specialize in?
Nordic Group B.V. is focused on the development and commercialization of specialized pharmaceutical products across various therapeutic areas.
